Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a
monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the …

Vascular endothelial growth factor receptors (VEGFRs) are a family of receptor protein
tyrosine kinases that play an important role in the regulation of tumor-induced angiogenesis …

Antibody-drug conjugates (ADCs) are complex engineered therapeutics consisting of
monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent …

Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the
treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 …

Simple Summary Antibody–drug conjugates (ADC) have shown remarkable therapeutic
activity in a wide range of hematologic and solid tumors. Herein, we discuss the …

Abstract Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal
antibodies with precise targeting and payloads with efficient killing, show great clinical …

Since the first approval of gemtuzumab ozogamicin (Mylotarg; Pfizer; CD33 targeted), two
additional antibody–drug conjugates (ADC), brentuximab vedotin (Adcetris; Seattle …

Antibody-drug conjugates (ADCs) are cancer therapeutic agents comprised of an antibody,
a linker and a small-molecule payload. ADCs use the specificity of the antibody to target the …

Antibody‐based cancer therapy, one of the most significant therapeutic strategies, has
achieved considerable success and progress over the past decades. Nevertheless …

In recent years, antibody-drug conjugates (ADCs) have become promising antitumor agents
to be used as one of the tools in personalized cancer medicine. ADCs are comprised of a …